ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Healy Names President, CEO of Red Cross; AMA Supports annual Mammograms for 40+

July 16, 1999

Bonner to Succeed Stovall as NCCS President and CEO.

May 30, 2008

NCAB Member Seeks Broder’s Resignation, Gets No support

June 3, 1994

In Brief: NIH Appeals Board Restores Nassau CCOP Funding, PI Says It Is Now Meeting Patient Accrual Goal

February 22, 1985

In Brief: NCI Future Budget Planning Now In Open; One Or Two comp Centers In 12-18 Months

May 28, 1976

In Brief: Data Availability From Cancer Survey Presents Problems – Who Gets It first, Confidentiality

August 30, 1974